Pfizer paying US$14b for Medivation
Print Edition
PFIZER will pay about US$14 billion in cash for cancer drug company Medivation, a deal that will add the pricey late-stage prostate cancer treatment Xtandi to its oncology portfolio.
The New York drugmaker said yesterday that it will pay US$81.50 per Medivation share. That’s a 21 percent premium to the San Francisco biotech’s Friday closing price of US$67.19.
Medivation Inc and Japanese drugmaker Astellas Pharma jointly market Xtandi, with Astellas selling the drug outside the United States.
Xtandi drew attention earlier this year from the public interest group Knowledge Economy International, which petitioned the National Institutes of Health to reduce the US$129,000-a year list price for the advanced prostate cancer treatment. The government declined.
Knowledge Ecology and the Union for Affordable Cancer Treatment said the price on Xtandi, which amounts to US$88.48 per pill, is two to four times the price in other wealthy countries.
The US government covers much of the cost for Xtandi prescriptions filled under federal health programs such as Medicare, Medicaid and the Veterans Administration.
Medivation focuses on developing medicines for cancer and serious diseases with few treatment options. The drugmaker brought in US$943 million in revenue last year.
Aside from Xtandi, Pfizer Inc said Medivation also has a promising pipeline of cancer drugs in late-stage clinical development. That includes the potential breast cancer treatment talazoparib and a potential lymphoma drug. Researchers also are studying Xtandi as a possible treatment for earlier-stage prostate cancer.
The boards of both companies have approved the deal, which is targeted to close in the third or fourth quarter. Pfizer, which makes the erectile dysfunction treatment Viagra and fibromyalgia, expects to finance it with existing cash.
The deal comes about three months after Medivation rejected a US$9.3 billion takeover bid from France’s Sanofi.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
